Destruxin D is a natural compound, which is retrieved from Metarhizium anisopliae. None pharmacological or bio-effective information for destruxin D.

WAY-213613 to be a potent, EAAT2-preferring, competitive nonsubstrate inhibitor of EAAT2. WAY-213613 was devoid of either agonist or antagonist activity at the ionotropic NMDA and AMPA receptors expressed natively in cultured hippocampal neurons, or at the human mGlu receptors 1, 2, and 4 heterologously expressed in stable cell lines. It is used in scientific research into the function of the glutamate transporters.

(R)-3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine is a chemical precursor of BTK inhibitor ibrutinib and related compounds. (R)-3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine lacks the propenamide group that is responsible for covalent binding to cysteine residue of BTK kinase.

It is known, that SRT3109 is a ligand of CXCR2 for use in the treatment of chemokine mediated diseases and conditions. Others information is not available.

Nicotine-1'-N-oxide (NNO) is an oxidation product of nicotine. Flavin-containing monooxygenase is responsible for the oxygen transfer. Nicotine N'- oxide is a primary metabolite of nicotine, although only about 4-7% of nicotine absorbed by smokers is metabolized via this route. It appears that NNO is not further metabolized to any significant extent, except by reduction back to nicotine, which may lead to recycling of nicotine in the body.

There is no information about biological and pharmacological application of lead maleate. It is known, that this is insoluble in water salt of lead and oleic acid. This substance is a toxic, with teratogenic and carcinogenic properties.

3,5-Diiodo-L-thyronine (3,5-T2), a potential metabolite of 3,3',5-triiodothyronine (T3), is an active thyroid hormone. It acts as an alternative ligand for thyroid hormone receptor beta. 3,5-Diiodo-L-thyronine has the capacity to stimulate hepatic lipid catabolism but acts by different from T3 molecular mechanisms to achieve this effect.

Prostaglandin H2 (PGH2) is a type of Prostaglandin which is derived from arachidonic acid and is a precursor for many other biologically significant molecules. Prostaglandins are synthesized from arachidonic acid by the prostaglandin-endoperoxide synthase enzymes, which are also called Cyclooxygenases. These enzymes generate a reactive intermediate PGH2 which has a reasonably long half-life (90-100 s). PGH2 is converted into the biologically active prostaglandins by prostaglandin isomerases, yielding Prostaglandin E2, D2 and F2 (PGE2, PGD2, and PGF2), or by thromboxane synthase to make Thromboxane A2 (TxA2) or by prostacyclin synthase to make Prostaglandin I2 (PGI2). Prostaglandin H2 was first isolated from incubations of arachidonic acid with ovine seminal vesicle microsomes, and was described as a potent vasoconstrictor. Thromboxane receptors can be activated by PGH2 and TxA2, as well as isoprostanes, all of which produce vasoconstriction. Activation of TP receptors by either PGH2 or TxA2 contributes to hypertension of pregnancy and to the elevation of blood pressure in some forms of experimental hypertension, particularly those that involve activation of the renin-angiotensin system.

Ferric stearate is an Iron(III) salt of stearic acid, used as a component of plastic decomposition accelerators.

The ciclosporin analogue ciclosporin H is a potent and selective inhibitor of mediator release from basophils induced by activation of the formyl peptide receptor, and therefore has potential as an anti-inflammatory agent. It acts by interfering with agonist binding to formylmethionylleucylphenylalanine (FMLP) receptors. Unlike ciclosporin [ciclosporin A], ciclosporin H has Dmethyl valine (rather than the Lisomer) at position 11, has an extremely low affinity for cyclophilin, and is devoid of immunosuppressive activity. Ciclosporin H was undergoing preclinical investigation with researchers at the University of Naples Federico II in Italy as an antiinflammatory agent. However, no recent development has been reported.